STAT

Opinion: Innovative ways to pay for new antibiotics will help fight superbugs

Without inventive approaches to funding the development of new antibiotics, we risk living — and dying — in a post-antibiotic era.
A computer-generated image of a cluster of drug-resistant Campylobacter bacteria. Source: James Archer/CDC

Antibiotics are the most important drug class in human history. Without them, minor infections like strep throat or urinary tract infections could turn deadly. Heart surgery, cancer treatment, and virtually everything else that happens in a hospital would be far more dangerous than it is today. But if we keep taking them for granted, and fail to provide innovative approaches to funding the development of new antibiotics, drug-resistant microbes will get the upper hand.

Although we’ve made great strides in the development of antibiotics since the discovery of penicillin in the early 20th century, we aren’t keeping up with the — common bacteria that have acquired genes that make them resistant to most or all of our antibiotics. “[T]he end of the road isn’t very far away for antibiotics,” Dr. Tom Frieden, the former head of the Centers for.

You're reading a preview, sign up to read more.

More from STAT

STAT7 min readTech
One Health Care Startup At A Time, This Venture Capitalist Wants To Harness The Investing Power Of Women
“If women want specific companies in the world that address their needs, the only way to do that is for women to become the investors."
STAT4 min readSociety
Opinion: Bringing Transparency To The Notion Of Price Transparency
Transparency is not just a goal. It's also an ethic. Organizations involved in price transparency initiatives should be transparent in the ways appropriate to them.
STAT1 min read
Listen: The Serious Side Of Spit Kits, How BiTEs Leave A Mark, & Sarepta’s Sluggish Study
Is anything too weighty to be explained over the internet? Can a new spin on old technology outfox CAR-T? And does that controversial drug even work? We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Fi